Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market
Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.
Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.